Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedMar 27, 2026
DataAggregated Company Financials
Companies7
  • 7D4.0%
  • 3M-5.2%
  • 1Y-10.5%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 4.0%, with Lonza Group up 4.4%. However, the industry is down 10% over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 27 Mar 2026CHF 46.4bCHF 10.1bCHF 1.1b32.3x40.5x4.6x
Sun, 22 Feb 2026CHF 50.1bCHF 10.1bCHF 1.3b32x38.8x5x
Tue, 20 Jan 2026CHF 51.2bCHF 10.6bCHF 1.1b32.6x46.6x4.8x
Thu, 18 Dec 2025CHF 47.6bCHF 10.6bCHF 1.1b27.6x43.3x4.5x
Sat, 15 Nov 2025CHF 49.1bCHF 10.6bCHF 1.1b28.3x44.6x4.6x
Mon, 13 Oct 2025CHF 48.8bCHF 10.6bCHF 1.1b30.7x44.4x4.6x
Wed, 10 Sep 2025CHF 52.6bCHF 10.6bCHF 1.1b32.8x47.8x4.9x
Fri, 08 Aug 2025CHF 52.0bCHF 10.7bCHF 1.1b33.4x45.2x4.9x
Sun, 06 Jul 2025CHF 52.4bCHF 10.1bCHF 1.0b33.6x50.5x5.2x
Tue, 03 Jun 2025CHF 52.6bCHF 10.1bCHF 1.0b30.6x50.6x5.2x
Thu, 01 May 2025CHF 53.9bCHF 10.1bCHF 1.0b30.7x51.9x5.3x
Sat, 29 Mar 2025CHF 53.1bCHF 10.1bCHF 1.0b33.1x51.8x5.3x
Mon, 24 Feb 2025CHF 56.2bCHF 10.1bCHF 1.0b33x54.1x5.6x
Wed, 22 Jan 2025CHF 55.4bCHF 10.2bCHF 943.3m35.5x58.7x5.4x
Fri, 20 Dec 2024CHF 52.2bCHF 10.2bCHF 943.6m36.4x55.4x5.1x
Sun, 17 Nov 2024CHF 52.2bCHF 10.2bCHF 943.5m40.6x55.3x5.1x
Tue, 15 Oct 2024CHF 54.1bCHF 10.2bCHF 943.5m41.4x57.4x5.3x
Thu, 12 Sep 2024CHF 56.7bCHF 10.2bCHF 937.1m44.4x60.5x5.6x
Sat, 10 Aug 2024CHF 57.4bCHF 10.2bCHF 924.0m45.2x62.2x5.6x
Mon, 08 Jul 2024CHF 54.3bCHF 10.3bCHF 1.0b46.3x54.2x5.3x
Wed, 05 Jun 2024CHF 52.2bCHF 10.3bCHF 1.0b42.6x52.1x5.1x
Fri, 03 May 2024CHF 54.0bCHF 10.3bCHF 1.0b43.3x53.9x5.3x
Sun, 31 Mar 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Tue, 27 Feb 2024CHF 50.4bCHF 10.2bCHF 982.3m46.7x51.4x5x
Thu, 25 Jan 2024CHF 42.7bCHF 9.8bCHF 1.5b31.6x28.6x4.4x
Sat, 23 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Mon, 20 Nov 2023CHF 41.5bCHF 9.8bCHF 1.5b29.5x27.8x4.2x
Wed, 18 Oct 2023CHF 46.1bCHF 9.8bCHF 1.5b30.7x30.8x4.7x
Fri, 15 Sep 2023CHF 51.9bCHF 9.8bCHF 1.5b35.1x34.8x5.3x
Sun, 13 Aug 2023CHF 53.2bCHF 9.8bCHF 1.5b35.9x34.4x5.4x
Tue, 11 Jul 2023CHF 55.0bCHF 9.7bCHF 1.6b35.9x33.6x5.7x
Thu, 08 Jun 2023CHF 60.5bCHF 9.7bCHF 1.6b37.5x37x6.3x
Sat, 06 May 2023CHF 62.0bCHF 9.7bCHF 1.6b41.3x38x6.4x
Mon, 03 Apr 2023CHF 58.1bCHF 9.7bCHF 1.7b42x34.8x6x
Price to Earnings Ratio

34.8x


Total Market Cap: CHF 58.1bTotal Earnings: CHF 1.7bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 46x202420252026
Current Industry PE
  • Investors are pessimistic on the Swiss Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.5x which is lower than its 3-year average PE of 46.0x.
  • The 3-year average PS ratio of 5.1x is higher than the industry's current PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market1.39%
Healthcare2.29%
Life Sciences3.99%
Clinical Research and Equipment3.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 494.204.4%
+CHF 1.5b		-11.6%PE38.2x
BANB Bachem HoldingCHF 64.153.3%
+CHF 153.6m		19.3%PE32.3x
TECN Tecan GroupCHF 128.108.4%
+CHF 124.1m		-25.4%PS1.8x
PPGN PolyPeptide GroupCHF 27.359.8%
+CHF 80.9m		59.9%PS2.5x
XLS Xlife SciencesCHF 21.400.5%
+CHF 576.8k		-9.3%PE4x

Latest News

SFZN
CHF 73.40
Siegfried Holding
7D
-1.5%
1Y
-19.9%
SKAN
CHF 44.45
SKAN Group
7D
-0.1%
1Y
-38.7%
TECN
CHF 128.10
Tecan Group
7D
8.4%
1Y
-25.4%
BANB
CHF 64.15
Bachem Holding
7D
3.3%
1Y
19.3%

BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential

Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.
PPGN
CHF 27.35
PolyPeptide Group
7D
9.8%
1Y
59.9%
LONN
CHF 494.20
Lonza Group
7D
4.4%
1Y
-11.6%
XLS
CHF 21.40
Xlife Sciences
7D
0.5%
1Y
-9.3%